

Freedom of Information Request - FOI2024/328

Thank you for your Freedom of Information request.

How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Apremilast
- Bimekizumab
- Brodalumab
- Certolizumab
- Deucravacitinib
- Dimethyl fumarate
- Etanercept - Enbrel
- Etanercept Biosimilar
- Guselkumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Ixekizumab
- Risankizumab
- Secukinumab
- Tildrakizumab
- Ustekinumab
- Ustekinumab Biosimilar
- Omalizumab

I have considered your request and have set out the Trust's response below:

Description	Patient Count
Adalimumab - Humira	30
Adalimumab Biosimilar	0
Apremilast	Less than 6*
Bimekizumab	Less than 6*
Brodalumab	Less than 6*
Certolizumab	Less than 6*

Glen Burley, Chief Executive

Russell Hardy, Chairman

Deucravacitinib	0
Dimethyl fumarate	0
Etanercept - Enbrel	0
Etanercept Biosimilar	0
Guselkumab	0
Infliximab - Remicade	0
Infliximab Biosimilar	0
Ixekizumab	6
Risankizumab	27
Secukinumab	19
Tildrakizumab	Less than 6*
Ustekinumab	24
Ustekinumab Biosimilar	0
Omalizumab	0

* Please note that the exact number of patients has been withheld and instead a range of below 6 has been provided, as this relates to a low number. Statistically low information can potentially identify individuals' data, especially due to the rural nature and low population of the county. It would be, in my view, possible to identify them if this data were to be provided to you. The data therefore consists of personal data and as such has been withheld under Section 40(2) of the Freedom of Information Act 2000.

Yours sincerely,
Freedom of Information Officer

Glen Burley, Chief Executive

Russell Hardy, Chairman